Published in Biotechniques on September 01, 1992
Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc Natl Acad Sci U S A (2005) 1.02
AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. J Neurosci (2009) 0.97
Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood (2011) 0.86
Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans. Thromb Haemost (2012) 0.81
Development of a microplate coagulation assay for Factor V in human plasma. Thromb J (2011) 0.78
Exactin: A specific inhibitor of Factor X activation by extrinsic tenase complex from the venom of Hemachatus haemachatus. Sci Rep (2016) 0.75
Measurement of factor v activity in human plasma using a microplate coagulation assay. J Vis Exp (2012) 0.75
Mutation of the Kunitz-type proteinase inhibitor domain in the amyloid β-protein precursor abolishes its anti-thrombotic properties in vivo. Thromb Res (2017) 0.75
A cell-based model of hemostasis. Thromb Haemost (2001) 2.99
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. Am J Hematol (1993) 1.92
Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost (2007) 1.89
Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost (2004) 1.72
Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost (2007) 1.56
A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost (2012) 1.54
Thrombin generation in vascular tissue. J Thromb Haemost (2006) 1.47
Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost (2012) 1.45
Platelets contain releasable coagulation factor IX antigen. Blood Coagul Fibrinolysis (1993) 1.39
Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis (1999) 1.29
TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost (1999) 1.15
High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol (2001) 1.12
Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood (1990) 1.10
Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol (1999) 1.10
Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol (2000) 1.05
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis (1998) 1.04
Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. J Thromb Haemost (2006) 0.99
Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood (1995) 0.98
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol (2001) 0.96
Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest (1997) 0.96
Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch Biochem Biophys (1995) 0.96
A rapid method to isolate platelets from human blood by density gradient centrifugation. Am J Clin Pathol (1992) 0.92
Recombinant activated factor VII and the anaesthetist. Anaesthesia (2005) 0.92
Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost (2004) 0.87
Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood (1992) 0.87
Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever. Infect Immun (1982) 0.86
Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. J Biol Chem (1990) 0.86
Deencryption of cellular tissue factor is independent of its cytoplasmic domain. Biochem Biophys Res Commun (2000) 0.86
Interaction of substrates with glutamine synthetase after limited proteolysis. Biochemistry (1984) 0.85
Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost (1997) 0.84
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood (1994) 0.84
Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res (1989) 0.84
Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa. J Biol Chem (1996) 0.83
Wound healing in haemophilia--breaking the vicious cycle. Haemophilia (2010) 0.83
Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost (2011) 0.82
Cellular interactions in hemostasis. Haemostasis (1996) 0.82
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg"). J Biol Chem (1990) 0.82
Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb Haemost (1992) 0.82
Newer concepts of blood coagulation. Haemophilia (1998) 0.81
Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules. J Biol Chem (1990) 0.81
Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry (1998) 0.81
Prediction of solution structures of the Ca2+-bound gamma-carboxyglutamic acid domains of protein S and homolog growth arrest specific protein 6: use of the particle mesh Ewald method. Biophys J (1997) 0.81
Variability in platelet procoagulant activity in healthy volunteers. Thromb Res (1996) 0.81
Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: communication from the SSC of the ISTH. J Thromb Haemost (2014) 0.80
The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis (2000) 0.78
Calcium enhances factor Xa activity independent of gamma-carboxyglutamic acid residues. Thromb Res (1988) 0.78
Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition. J Biol Chem (1997) 0.78
Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. J Thromb Haemost (2013) 0.78
Comparison of lipid binding and kinetic properties of normal, variant, and gamma-carboxyglutamic acid modified human factor IX and factor IXa. Biochemistry (1985) 0.78
The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost (1997) 0.78
Links between the immune and coagulation systems: how do "antiphospholipid antibodies" cause thrombosis? Immunol Res (2000) 0.77
p-Amidino esters as irreversible inhibitors of factors IXa and Xa and thrombin. Biochemistry (1986) 0.77
Structural and enzymatic properties of Escherichia coli glutamine synthetase subjected to limited proteolysis. Curr Top Cell Regul (1985) 0.77
Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost (1998) 0.76
Prothrombin times on deficient plasma reconstituted with factors IX and X. Am J Hematol (1994) 0.75
Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. J Thromb Haemost (2004) 0.75
Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Haemophilia (1997) 0.75
The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagul Fibrinolysis (1998) 0.75
Activation of normal and abnormal human factor IX with trypsin. Arch Biochem Biophys (1985) 0.75
Inflammation does not predispose to bleeding in hemophilia. J Thromb Haemost (2010) 0.75
Is Ca(II) ion binding to prothrombin fragment 1 intrinsically cooperative, or is the cooperative binding accounted for by self-association? Blood Coagul Fibrinolysis (1995) 0.75
Celecoxib does not delay cutaneous wound healing in haemophilia B mice. Haemophilia (2009) 0.75
Platelet activation in patients with thrombotic thrombocytopenic purpura. Am J Hematol (1993) 0.75
Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI). Thromb Haemost (1998) 0.75
Nontoxic irreversible inhibitors of factors IXa, Xa, and thrombin: potential therapeutic agents for the in vivo regulation of thrombin generation and activity. Ann N Y Acad Sci (1986) 0.75